Sign in
Not yet taking people in United StatesPhase 4

Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia

Key facts

Who runs it
University of Maryland, Baltimore
Where
Baltimore, Glen Burnie, and Towson, United StatesSee the 4 sites
Trial code
Status
Not yet recruiting
Phase
Phase 4
People taking part
900 people, planned
Starts
1 Feb 2027
Expected to end
30 Sept 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Ceftriaxone 1 gram daily
  • Ceftriaxone 2 grams daily
Record updated
5 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (4)Hide the full registry criteria

Who can take part

  • Evaluated in the emergency department or within 72 hours of hospitalization
  • Prescribed Ceftriaxone for community-acquired pneumonia

Who cannot take part

  • Respiratory failure requiring mechanical ventilation, non-invasive ventilation such as bilevel positive airway pressure, or high flow nasal cannula
  • Planned or present admission to an intensive care unit

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Community acquired pneumonia

Where in United States

  • University of Maryland Medical CenterBaltimore, United StatesContact: Megan Dunning, MDNot yet recruiting
  • University of Maryland Medical Center - Midtown CampusBaltimore, United StatesContact: Jonathan Baghdadi, MD, PhDNot yet recruiting
  • UM Baltimore Washington Medical CenterGlen Burnie, United StatesContact: Stephanie Pires, PharmDNot yet recruiting
  • University of Maryland St. Joseph Medical CenterTowson, United StatesContact: Rose Kohinke, PharmDNot yet recruiting

About the trial

What the trial wants to find out

Aim: Demonstrate the equivalent efficacy and superior safety of Ceftriaxone 1 gram daily compared with Ceftriaxone 2 grams daily among hospitalized patients with community-acquired pneumonia who are not admitted to the intensive care unit.<p>

Read full original descriptionShow less

Hypothesis: Among hospitalized patients outside of the intensive care unit with community-acquired pneumonia who are prescribed Ceftriaxone, a dosage of 1 gram daily will be associated with an equivalent rate of clinical cure and fewer adverse events than a dosage of 2 grams daily.

The 2 groups in the trial

  • Low Dose CeftriaxoneExisting treatment, for comparison

    Intravenous Ceftriaxone will be dosed 1 gram daily per institutional guidance for treatment of community-acquired pneumonia outside of the intensive care unit.

    Treatment: Ceftriaxone 1 gram daily

  • Moderate Dose CeftriaxoneExisting treatment, for comparison

    Intravenous Ceftriaxone will be dosed 2 grams daily per institutional guidance for treatment of community-acquired pneumonia outside of the intensive care unit.

    Treatment: Ceftriaxone 2 grams daily

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pragmatic Randomized Trial Evaluating Dosage of Ceftriaxone for Community-Acquired Pneumonia Outside the Intensive Care Unit
Criteria questions
Built from NCT07537413, who can take part
Record updated
5 November 2026